A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity [MARITIME-CV] (NCT07037433)

Maritime CV

This trial is Currently recruiting
Registration number NCT07037433
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Program & service

This trial is being run with the Heart & Lung service, and as part of the Cardiology program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

A/Prof James Shaw

Key inclusion data

Inclusion Criteria: Age ? 45 years; BMI of ? 27 kg/m2; History of Atherosclerotic Cardiovascular Disease (ASCVD) as evidenced by at least one of Prior MI/Prior ischemic stroke/Symptomatic peripheral arterial disease (PAD).

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.